Rice Hall James & Associates LLC Has $2.01 Million Stock Position in Pacira BioSciences, Inc. $PCRX

Rice Hall James & Associates LLC cut its position in Pacira BioSciences, Inc. (NASDAQ:PCRX) by 51.0% in the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 88,844 shares of the company’s stock after selling 92,411 shares during the quarter. Rice Hall James & Associates LLC’s holdings in Pacira BioSciences were worth $2,008,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Northwestern Mutual Wealth Management Co. raised its stake in Pacira BioSciences by 5,900.0% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 1,500 shares of the company’s stock worth $39,000 after buying an additional 1,475 shares during the period. Meeder Asset Management Inc. acquired a new stake in Pacira BioSciences in the first quarter valued at approximately $46,000. Kestra Advisory Services LLC acquired a new stake in Pacira BioSciences in the fourth quarter valued at approximately $48,000. Eurizon Capital SGR S.p.A. bought a new stake in shares of Pacira BioSciences during the fourth quarter valued at approximately $51,000. Finally, Global Retirement Partners LLC raised its position in shares of Pacira BioSciences by 479.4% during the fourth quarter. Global Retirement Partners LLC now owns 2,028 shares of the company’s stock worth $52,000 after purchasing an additional 1,678 shares during the period. 99.73% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research firms recently issued reports on PCRX. Royal Bank Of Canada lifted their price target on shares of Pacira BioSciences from $22.00 to $24.00 and gave the company a “sector perform” rating in a research report on Friday, May 1st. Weiss Ratings raised shares of Pacira BioSciences from a “sell (d)” rating to a “sell (d+)” rating in a research note on Wednesday, May 20th. HC Wainwright reiterated a “buy” rating and set a $38.00 price objective on shares of Pacira BioSciences in a report on Wednesday, July 1st. Needham & Company LLC boosted their target price on shares of Pacira BioSciences from $30.00 to $32.00 and gave the stock a “buy” rating in a research report on Friday, May 1st. Finally, Zacks Research upgraded shares of Pacira BioSciences from a “strong sell” rating to a “hold” rating in a report on Tuesday, April 7th. Three equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $29.40.

Pacira BioSciences Stock Performance

Shares of PCRX stock opened at $25.88 on Monday. The company has a debt-to-equity ratio of 0.56, a quick ratio of 3.35 and a current ratio of 4.73. The company has a market capitalization of $1.02 billion, a price-to-earnings ratio of 215.68 and a beta of 0.27. Pacira BioSciences, Inc. has a 52-week low of $18.80 and a 52-week high of $27.64. The company has a 50-day simple moving average of $24.09 and a two-hundred day simple moving average of $23.18.

Pacira BioSciences (NASDAQ:PCRX) last posted its earnings results on Thursday, April 30th. The company reported $0.60 EPS for the quarter, missing the consensus estimate of $0.61 by ($0.01). Pacira BioSciences had a return on equity of 10.24% and a net margin of 0.70%.The firm had revenue of $177.38 million for the quarter, compared to the consensus estimate of $171.80 million. During the same period in the prior year, the business earned $0.65 EPS. Pacira BioSciences’s quarterly revenue was up 5.0% compared to the same quarter last year. Research analysts anticipate that Pacira BioSciences, Inc. will post 1.94 EPS for the current fiscal year.

Insider Activity

In other news, SVP Lauren Riker sold 6,115 shares of Pacira BioSciences stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $23.50, for a total transaction of $143,702.50. Following the sale, the senior vice president directly owned 62,284 shares in the company, valued at $1,463,674. The trade was a 8.94% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.40% of the stock is currently owned by corporate insiders.

Pacira BioSciences Profile

Pacira BioSciences, Inc is a specialty pharmaceutical company focused on developing and commercializing non-opioid, non-addictive pain management and regenerative health solutions. The company’s flagship product, EXPAREL, is a bupivacaine liposome injectable suspension designed to provide long-lasting postsurgical analgesia. EXPAREL is used by clinicians across a broad range of surgical procedures to reduce reliance on opioid medications and to help manage acute postoperative pain.

In addition to its marketed offering, Pacira maintains an active pipeline of investigational products aimed at addressing unmet needs in pain management and inflammation control.